SAVOR trial: how may the largest DPP-4 inhibitor CV safety study influence day-to-day clinical practice?
Barcelona, Spain, 23-Sep-13
Welcome and introduction
Nauck, Prof. M. A. / Barnett, Prof. A.
From UKPDS to SAVOR: the evolving landscape of CV outcomes studies in type 2 diabetes
Barnett, Prof. A.
Introducing the latest CV safety studies in type 2 diabetes
Mannucci, Dr. E.
Key findings from the SAVOR study: the effects of saxagliptin
Darius, Prof. Dr. H.
The potential impact of SAVOR on clinical practice
Mathieu, Prof. Ch.
Nauck, Prof. M. A.
How could we transform treatment in type 2 diabetes: which approach, when and for whom?
Nauck, Prof. M. A. / Mannucci, Dr. E. / Darius, Prof. Dr. H. / Mathieu, Prof. Ch. / Vilsboll, Dr. T. / Hadjadj, Dr. S. / Rossing, Dr. P.